Alzheimer's therapeutic development
CONDUCTink is a biotechnology company that delivers perfusable in-vitro models for preclinical Alzheimer's therapeutic discovery. Founded in 2023 by Louis Paone and Peter Galie, Ph.D., an associate professor of biomedical engineering, the company developed a platform to screen drugs related to Alzheimer's disease with the goal of ultimately replacing animal models.
The Galie lab at Rowan University completes the 4-week NSF Northeast Regional I-Corps program conducting customer discovery for spinal cord injury therapeutics
CONDUCTink is founded by Peter Galie, Ph.D. and Louis S. Paone spinning out of Rowan Universities department of Biomedical Engineering
Louis S. Paone's manuscript “A 3D-printed blood-brain barrier model with tunable topology and cell-matrix interactions” is published in Biofabrication
CONDUCTink completes the 7-week NSF National I-Corp program conducting over +100 in-person customer discovery interviews across the country for Alzheimer's drug discovery
A strategic partnership with Vitroscope is launched
Louis S. Paones manuscript “Effects of Drag-Reducing Polymers on Hemodynamics and Whole Blood-Endothelial Interactions in 3D-Printed Vascular Topologies” in ACS Applied Materials & Interfaces
A strategic partnership with Etaluma, Inc. is launched